Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mersana Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Mersana Therapeutics, Inc.

MRSN

Mersana Therapeutics, Inc.

About Mersana Therapeutics, Inc.

Mersana Therapeutics is a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. Its proprietary platforms, Dolasynthen and Immunosynthen, enable targeted delivery of cytotoxic and immunostimulatory agents. The company focuses on innovative therapies for unmet cancer needs, collaborating with industry leaders to advance clinical-stage ADCs targeting various tumor antigens, aiming to improve safety, efficacy, and patient outcomes.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Mersana Therapeutics, Inc.

1
1
Mersana Therapeutics, Inc. Mersana Therapeutics Reports Q3 2025 Net Loss of $7.5 Million, Announces Proposed Acquisition

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Mersana Therapeutics, Inc. Mersana Therapeutics Reports $24.3 Million Net Loss in Q2 2025, Revenue Declines

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Mersana Therapeutics, Inc. Mersana Therapeutics Reports $24.1 Million Net Loss and Announces Major Restructuring Plan

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Mersana Therapeutics, Inc. Mersana Therapeutics Reports $69.2 Million Net Loss for 2024, Collaboration Revenue Increases

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Mersana Therapeutics, Inc. Mersana Therapeutics Reports Improved Financials, Reduced Expenses, and Focus on Lead Product Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments